Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance.
Ki-67 is a monoclonal antibody which recognises a human nuclear antigen expressed in proliferating cells. The antibody was used to assess proliferation in primary human bladder tumours from 64 patients. Ki-67 index (the number of Ki-67 positive tumour cells divided by the total number of tumour cells %) was derived from 59 tumours. A wide range of Ki-67 indices were recorded, range 3.0-65.8%, mean 20.2%. The Ki-67 index correlated with known prognostic factors: T stage (P = 0.002) and histological grade (P less than 0.001), early stage disease and more differentiated tumours having lower Ki-67 indices. Patients with invasive disease (21 patients) had significantly higher Ki-67 indices than those with non-invasive disease (P = 0.01). Patients with metastatic disease at presentation (four cases) all had a Ki-67 index of greater than or equal to 29%. Ki-67 antibody staining is a simple technique for assessing the proliferation fraction than can be performed on a small amount of tissue taken at routine biopsy without prior injection of thymidine analogues.
Bush
C
C
Radiotherapy Research Unit, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK.
Price
P
P
Norton
J
J
Parkins
C S
CS
Bailey
M J
MJ
Boyd
J
J
Jones
C R
CR
A'Hern
R P
RP
Horwich
A
A
D000368:Aged; D000911:Antibodies, Monoclonal; D001706:Biopsy; D002455:Cell Division; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen; D009687:Nuclear Proteins